MyVax Cancer Vaccine Failure Could Be Due To Active Comparator – Genitope
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A failed primary endpoint for Genitope's Phase III trial of follicular non-Hodgkin's lymphoma vaccine MyVax was due to a comparator group that was found to be active, the company said. The firm announced in a Dec. 20 conference call that its lead drug candidate MyVax elicited an immune response in just 40 percent of patients enrolled in the trial and failed to meet its primary endpoint of statistically significant progression-free survival compared to the control group